SCHEDULE: Vanguard Reports 0% Stake in Iovance Biotherapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership stake in Iovance Biotherapeutics Inc. following an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 6 to its Schedule 13G for Iovance Biotherapeutics Inc.
• Vanguard now reports 0 shares beneficially owned, representing 0% of the class of Common Stock.
• This change is due to an internal realignment at The Vanguard Group on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately, disaggregated from The Vanguard Group, Inc.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over these securities, in accordance with SEC Release No. 34-39538.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting an internal corporate realignment at Vanguard, with no direct positive or negative implications for Iovance Biotherapeutics' operational performance or value.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Iovance Biotherapeutics Inc.'s future performance or operations.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities..."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are used by passive investors to report beneficial ownership of 5% or more of a company's stock. This amendment indicates a significant administrative change in how The Vanguard Group reports its holdings, rather than a divestment of Iovance Biotherapeutics shares. The shares are now reported by Vanguard's subsidiaries, reflecting a disaggregation of reporting in line with SEC guidance.

Stakeholder Impact

• Shareholders of Iovance Biotherapeutics should be aware that The Vanguard Group, Inc. no longer directly reports beneficial ownership, but its underlying subsidiaries likely still hold the shares. This is primarily a reporting change, not a change in underlying investment.

Key Dates

Keywords

Iovance Biotherapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, SEC filing, common stock, corporate realignment